Clinical Trial Update: Recombinant Human Relaxin for the Treatment of Decompensated CHF [Phase 2]

View source ↗

Summary

A Phase 2 trial of recombinant human relaxin for decompensated congestive heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Recombinant Human Relaxin (relaxin)

Snippet

Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | Conditions: Congestive Heart Failure (CHF) | Phase 2 | Status: TERMINATED